Stefan Hohaus

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 145 publications

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

Journal: European journal of haematology
Published: July 24, 2026

Building an RWD Oncology Data Mart for Diffuse Large B-Cell Lymphoma: From Data Integration to Clinical Insight.

Building an RWD Oncology Data Mart for Diffuse Large B-Cell Lymphoma: From Data Integration to Clinical Insight.

Journal: Studies in health technology and informatics
Published: May 23, 2026

Classical Hodgkin Lymphoma Today.

Classical Hodgkin Lymphoma Today.

Journal: Mediterranean journal of hematology and infectious diseases
Published: May 12, 2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances
Published: April 16, 2026

Flow cytometric PD-L1 expression enhances identification of Reed-Sternberg cells in suspected Hodgkin lymphoma from lymph node biopsies.

Flow cytometric PD-L1 expression enhances identification of Reed-Sternberg cells in suspected Hodgkin lymphoma from lymph node biopsies.

Journal: Cytometry. Part B, Clinical cytometry
Published: March 14, 2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology
Published: February 16, 2026

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology
Published: December 07, 2025

Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells.

Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells.

Journal: Clinical and experimental medicine
Published: November 20, 2025

Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study.

Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study.

Journal: Diseases (Basel, Switzerland)
Published: October 29, 2025

Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic.

Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic.

Journal: Diagnostics (Basel, Switzerland)
Published: September 03, 2025

Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial.

Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial.

Journal: HemaSphere
Published: July 07, 2025

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Journal: Blood advances
Published: June 13, 2025
Showing 1-12 of 145

Last Updated: 09/26/2026